A peer-reviewed clinical study published in Biomedicines has found that daily supplementation with ProGo®, Hofseth BioCare ASA's salmon protein hydrolysate, improved multiple biomarkers associated with metabolic health and healthy ageing in overweight adults — while a protein-matched whey comparator did not produce the same effects over the same period.
The randomised, double-blind, active-controlled pilot study ran for 56 days and tracked outcomes relevant to both the GLP-1 signalling pathway and lean muscle mass accrual. The head-to-head design against whey — the category's dominant protein benchmark — is particularly significant for ingredient buyers and finished-formulation developers weighing marine-derived peptides against conventional dairy-sourced options.
The Clinical Signal
ProGo® is derived from Norwegian Atlantic salmon and processed into a bioactive peptide hydrolysate. Hydrolysis breaks intact proteins into shorter peptide chains that may be absorbed more rapidly and interact with gut-derived hormone receptors, including those that trigger GLP-1 secretion. GLP-1 (glucagon-like peptide-1) is an incretin hormone that modulates insulin release, appetite satiety, and gastric emptying — mechanisms at the centre of the weight-management category's fastest-growing clinical conversation.
The study's finding that ProGo® supported lean muscle mass gains alongside metabolic marker improvement positions it at the intersection of two high-growth segments: GLP-1 and weight-management-adjacent supplementation and muscle health and active nutrition. For operators developing products targeting body recomposition or metabolic wellness, that dual endpoint is a meaningful formulation story.
Market Positioning
Marine-sourced protein ingredients have gained momentum as clean-label, sustainable alternatives to soy and dairy proteins, but clinical differentiation has remained a gap. A published, double-blind, peer-reviewed trial in a recognised international journal gives Hofseth BioCare a substantiated structure-function claim foundation that most marine protein suppliers cannot yet match.
The GLP-1 angle is especially timely. Consumer and clinician interest in GLP-1 pathways has accelerated sharply alongside the mainstreaming of GLP-1 receptor agonist medications, creating demand for nutraceutical and functional food products that support similar metabolic outcomes through dietary means. An ingredient with clinical evidence linking it to endogenous GLP-1 activity is well-positioned for sports nutrition, healthy-ageing, and metabolic-wellness SKUs across both supplement and functional food formats.
Hofseth BioCare, listed on the Oslo Stock Exchange, sources its salmon raw material from Norwegian aquaculture and has built its ingredient portfolio around bioactive marine peptides. ProGo® is available as a white-label ingredient for co-manufacturing partnerships and finished-formulation licensing. The Biomedicines publication provides the evidentiary backbone brands will need to carry structure-function claims through regulatory review in the US, EU, and key Asia-Pacific markets.
For trade buyers, the 56-day study duration and active comparator design — rather than placebo-only — represent a higher evidentiary standard than much of the marine protein literature, making the data more defensible in both labelling and retail communication contexts.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.
